APO Research
Talk to an analyst

APO RESEARCH · REPORT

Interleukin 1 Alpha

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Interleukin 1 Alpha Market Outlook and Growth Opportunities 2026

19 December 2025190 pages

Choose your research edition.

Industry ResearchInterleukin 1 Alpha Industry Research Report 2026113 pages · $2,950 USDIndustry Growth & TrendsGlobal Interleukin 1 Alpha Industry Growth and Trends Forecast to 203274 pages · $3,450 USDMarket StructureGlobal Interleukin 1 Alpha Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032170 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Interleukin 1 Alpha Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Interleukin 1 Alpha Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Interleukin 1 Alpha market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Interleukin 1 Alpha is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Interleukin 1 Alpha is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Interleukin 1 Alpha is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Interleukin 1 Alpha market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Interleukin 1 Alpha market include Handok Inc, XBiotech Inc and AbbVie Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Interleukin 1 Alpha market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Interleukin 1 Alpha and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Interleukin 1 Alpha sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Interleukin 1 Alpha market size, projected growth trends, production technologies, key applications, and end-use industries.

Interleukin 1 Alpha Segment by Company

Handok Inc

XBiotech Inc

AbbVie Inc

Interleukin 1 Alpha Segment by Type

HL-2351

CV-18C3

ABT-981

Others

Interleukin 1 Alpha Segment by Application

Hospital

Clinic

Research Center

Interleukin 1 Alpha Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Interleukin 1 Alpha status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Interleukin 1 Alpha market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Interleukin 1 Alpha significant trends, drivers, influence factors in global and regions.

6. To analyze Interleukin 1 Alpha competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Interleukin 1 Alpha market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Interleukin 1 Alpha and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Interleukin 1 Alpha.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Interleukin 1 Alpha market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Interleukin 1 Alpha industry.

Chapter 3: Detailed analysis of Interleukin 1 Alpha manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Interleukin 1 Alpha in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Interleukin 1 Alpha in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Interleukin 1 Alpha Industry Trends Table 2. Interleukin 1 Alpha Industry Drivers Table 3. Interleukin 1 Alpha Industry Opportunities and Challenges Table 4. Interleukin 1 Alpha Industry Restraints Table 5. Global Interleukin 1 Alpha Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Interleukin 1 Alpha Revenue Share by Company (2021-2026) Table 7. Global Interleukin 1 Alpha Sales Volume by Company (W Units) & (2021-2026) Table 8. Global Interleukin 1 Alpha Sales Volume Share by Company (2021-2026) Table 9. Global Interleukin 1 Alpha Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Interleukin 1 Alpha Company Ranking, (2024-2026) & (USD Million) Table 11. Global Interleukin 1 Alpha Key Company Manufacturing Base & Headquarters Table 12. Global Interleukin 1 Alpha Company, Product Type & Application Table 13. Global Interleukin 1 Alpha Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Interleukin 1 Alpha by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of HL-2351 Table 18. Significant Companies of CV-18C3 Table 19. Significant Companies of ABT-981 Table 20. Significant Companies of Others Table 21. Global Interleukin 1 Alpha Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 22. Global Interleukin 1 Alpha Sales Volume by Type (2021-2026) & (W Units) Table 23. Global Interleukin 1 Alpha Sales Volume by Type (2027-2032) & (W Units) Table 24. Global Interleukin 1 Alpha Sales Volume Share by Type (2021-2026) Table 25. Global Interleukin 1 Alpha Sales Volume Share by Type (2027-2032) Table 26. Global Interleukin 1 Alpha Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Interleukin 1 Alpha Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Interleukin 1 Alpha Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Interleukin 1 Alpha Sales Value Share by Type (2021-2026) Table 30. Global Interleukin 1 Alpha Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Hospital Table 32. Significant Companies of Clinic Table 33. Significant Companies of Research Center Table 34. Global Interleukin 1 Alpha Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 35. Global Interleukin 1 Alpha Sales Volume by Application (2021-2026) & (W Units) Table 36. Global Interleukin 1 Alpha Sales Volume by Application (2027-2032) & (W Units) Table 37. Global Interleukin 1 Alpha Sales Volume Share by Application (2021-2026) Table 38. Global Interleukin 1 Alpha Sales Volume Share by Application (2027-2032) Table 39. Global Interleukin 1 Alpha Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Interleukin 1 Alpha Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Interleukin 1 Alpha Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Interleukin 1 Alpha Sales Value Share by Application (2021-2026) Table 43. Global Interleukin 1 Alpha Sales Value Share by Application (2027-2032) Table 44. Global Interleukin 1 Alpha Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 45. Global Interleukin 1 Alpha Sales by Region (2021-2026) & (W Units) Table 46. Global Interleukin 1 Alpha Sales Market Share by Region (2021-2026) Table 47. Global Interleukin 1 Alpha Sales by Region (2027-2032) & (W Units) Table 48. Global Interleukin 1 Alpha Sales Market Share by Region (2027-2032) Table 49. Global Interleukin 1 Alpha Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Interleukin 1 Alpha Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Interleukin 1 Alpha Sales Value Share by Region (2021-2026) Table 52. Global Interleukin 1 Alpha Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Interleukin 1 Alpha Sales Value Share by Region (2027-2032) Table 54. Global Interleukin 1 Alpha Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global Interleukin 1 Alpha Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global Interleukin 1 Alpha Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 57. Global Interleukin 1 Alpha Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Interleukin 1 Alpha Sales by Country (2021-2026) & (W Units) Table 59. Global Interleukin 1 Alpha Sales Market Share by Country (2021-2026) Table 60. Global Interleukin 1 Alpha Sales by Country (2027-2032) & (W Units) Table 61. Global Interleukin 1 Alpha Sales Market Share by Country (2027-2032) Table 62. Global Interleukin 1 Alpha Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Interleukin 1 Alpha Sales Value Market Share by Country (2021-2026) Table 64. Global Interleukin 1 Alpha Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Interleukin 1 Alpha Sales Value Market Share by Country (2027-2032) Table 66. Handok Inc Company Information Table 67. Handok Inc Business Overview Table 68. Handok Inc Interleukin 1 Alpha Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Handok Inc Interleukin 1 Alpha Product Portfolio Table 70. Handok Inc Recent Development Table 71. XBiotech Inc Company Information Table 72. XBiotech Inc Business Overview Table 73. XBiotech Inc Interleukin 1 Alpha Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. XBiotech Inc Interleukin 1 Alpha Product Portfolio Table 75. XBiotech Inc Recent Development Table 76. AbbVie Inc Company Information Table 77. AbbVie Inc Business Overview Table 78. AbbVie Inc Interleukin 1 Alpha Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. AbbVie Inc Interleukin 1 Alpha Product Portfolio Table 80. AbbVie Inc Recent Development Table 81. Key Raw Materials Table 82. Raw Materials Key Suppliers Table 83. Interleukin 1 Alpha Distributors List Table 84. Interleukin 1 Alpha Customers List Table 85. Research Programs/Design for This Report Table 86. Authors List of This Report Table 87. Secondary Sources Table 88. Primary Sources List of Figures Figure 1. Interleukin 1 Alpha Product Image Figure 2. Global Interleukin 1 Alpha Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Interleukin 1 Alpha Sales Value (2021-2032) & (US$ Million) Figure 4. Global Interleukin 1 Alpha Sales (2021-2032) & (W Units) Figure 5. Global Interleukin 1 Alpha Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Interleukin 1 Alpha Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. HL-2351 Image Figure 10. CV-18C3 Image Figure 11. ABT-981 Image Figure 12. Others Image Figure 13. Global Interleukin 1 Alpha Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 14. Global Interleukin 1 Alpha Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Interleukin 1 Alpha Sales Volume Share by Type (2021-2032) Figure 16. Global Interleukin 1 Alpha Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Interleukin 1 Alpha Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Interleukin 1 Alpha Sales Value Share by Type (2021-2032) Figure 19. Hospital Image Figure 20. Clinic Image Figure 21. Research Center Image Figure 22. Global Interleukin 1 Alpha Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 23. Global Interleukin 1 Alpha Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Interleukin 1 Alpha Sales Volume Share by Application (2021-2032) Figure 25. Global Interleukin 1 Alpha Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Interleukin 1 Alpha Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Interleukin 1 Alpha Sales Value Share by Application (2021-2032) Figure 28. Global Interleukin 1 Alpha Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 29. Global Interleukin 1 Alpha Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Interleukin 1 Alpha Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Interleukin 1 Alpha Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Interleukin 1 Alpha Sales Value (2021-2032) & (US$ Million) Figure 33. North America Interleukin 1 Alpha Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Interleukin 1 Alpha Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Interleukin 1 Alpha Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Interleukin 1 Alpha Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Interleukin 1 Alpha Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Interleukin 1 Alpha Sales Value (2021-2032) & (US$ Million) Figure 39. South America Interleukin 1 Alpha Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Interleukin 1 Alpha Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Interleukin 1 Alpha Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Interleukin 1 Alpha Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Interleukin 1 Alpha Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Interleukin 1 Alpha Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Interleukin 1 Alpha Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Interleukin 1 Alpha Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Interleukin 1 Alpha Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Interleukin 1 Alpha Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Interleukin 1 Alpha Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Interleukin 1 Alpha Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Interleukin 1 Alpha Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Interleukin 1 Alpha Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Interleukin 1 Alpha Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Interleukin 1 Alpha Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Interleukin 1 Alpha Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Interleukin 1 Alpha Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Interleukin 1 Alpha Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Interleukin 1 Alpha Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Interleukin 1 Alpha Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Interleukin 1 Alpha Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Interleukin 1 Alpha Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Interleukin 1 Alpha Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Interleukin 1 Alpha Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Interleukin 1 Alpha Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Interleukin 1 Alpha Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Interleukin 1 Alpha Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Interleukin 1 Alpha Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Interleukin 1 Alpha Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Interleukin 1 Alpha Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Interleukin 1 Alpha Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Interleukin 1 Alpha Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Interleukin 1 Alpha Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Interleukin 1 Alpha Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Interleukin 1 Alpha Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Interleukin 1 Alpha Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Interleukin 1 Alpha Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Interleukin 1 Alpha Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Interleukin 1 Alpha Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Interleukin 1 Alpha Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Interleukin 1 Alpha Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Interleukin 1 Alpha Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Interleukin 1 Alpha Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Interleukin 1 Alpha Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Interleukin 1 Alpha Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Interleukin 1 Alpha Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Interleukin 1 Alpha Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Interleukin 1 Alpha Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Interleukin 1 Alpha Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Interleukin 1 Alpha Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Interleukin 1 Alpha Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Interleukin 1 Alpha Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Interleukin 1 Alpha Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Interleukin 1 Alpha Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Interleukin 1 Alpha Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Interleukin 1 Alpha Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Interleukin 1 Alpha Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Interleukin 1 Alpha Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Interleukin 1 Alpha Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Interleukin 1 Alpha Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Interleukin 1 Alpha Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Interleukin 1 Alpha Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Interleukin 1 Alpha Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Interleukin 1 Alpha Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Interleukin 1 Alpha Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Interleukin 1 Alpha Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Interleukin 1 Alpha Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Interleukin 1 Alpha Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Interleukin 1 Alpha Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Interleukin 1 Alpha Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Interleukin 1 Alpha Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Interleukin 1 Alpha Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Interleukin 1 Alpha Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Interleukin 1 Alpha Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Interleukin 1 Alpha Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Interleukin 1 Alpha Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Interleukin 1 Alpha Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Interleukin 1 Alpha Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Interleukin 1 Alpha Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Interleukin 1 Alpha Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Interleukin 1 Alpha Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Interleukin 1 Alpha Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Interleukin 1 Alpha Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Interleukin 1 Alpha Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Interleukin 1 Alpha Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Interleukin 1 Alpha Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Interleukin 1 Alpha Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Interleukin 1 Alpha Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • HL-2351
  • CV-18C3
  • ABT-981
  • Others
Applications
  • Hospital
  • Clinic
  • Research Center
Companies covered
  • Handok Inc
  • XBiotech Inc
  • AbbVie Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Interleukin 1 Alpha Sales Value (2021-2032)
  4. 1.2.2 Global Interleukin 1 Alpha Sales Volume (2021-2032)
  5. 1.2.3 Global Interleukin 1 Alpha Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Interleukin 1 Alpha Market Dynamics
  1. 2.1 Interleukin 1 Alpha Industry Trends
  2. 2.2 Interleukin 1 Alpha Industry Drivers
  3. 2.3 Interleukin 1 Alpha Industry Opportunities and Challenges
  4. 2.4 Interleukin 1 Alpha Industry Restraints
3 Interleukin 1 Alpha Market by Company
  1. 3.1 Global Interleukin 1 Alpha Company Revenue Ranking in 2025
  2. 3.2 Global Interleukin 1 Alpha Revenue by Company (2021-2026)
  3. 3.3 Global Interleukin 1 Alpha Sales Volume by Company (2021-2026)
  4. 3.4 Global Interleukin 1 Alpha Average Price by Company (2021-2026)
  5. 3.5 Global Interleukin 1 Alpha Company Ranking (2024-2026)
  6. 3.6 Global Interleukin 1 Alpha Company Manufacturing Base and Headquarters
  7. 3.7 Global Interleukin 1 Alpha Company Product Type and Application
  8. 3.8 Global Interleukin 1 Alpha Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Interleukin 1 Alpha Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Interleukin 1 Alpha Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Interleukin 1 Alpha Market by Type
  1. 4.1 Interleukin 1 Alpha Type Introduction
  2. 4.1.1 HL-2351
  3. 4.1.2 CV-18C3
  4. 4.1.3 ABT-981
  5. 4.1.4 Others
  6. 4.2 Global Interleukin 1 Alpha Sales Volume by Type
  7. 4.2.1 Global Interleukin 1 Alpha Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Interleukin 1 Alpha Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Interleukin 1 Alpha Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Interleukin 1 Alpha Sales Value by Type
  11. 4.3.1 Global Interleukin 1 Alpha Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Interleukin 1 Alpha Sales Value by Type (2021-2032)
  13. 4.3.3 Global Interleukin 1 Alpha Sales Value Share by Type (2021-2032)
5 Interleukin 1 Alpha Market by Application
  1. 5.1 Interleukin 1 Alpha Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Research Center
  5. 5.2 Global Interleukin 1 Alpha Sales Volume by Application
  6. 5.2.1 Global Interleukin 1 Alpha Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Interleukin 1 Alpha Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Interleukin 1 Alpha Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Interleukin 1 Alpha Sales Value by Application
  10. 5.3.1 Global Interleukin 1 Alpha Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Interleukin 1 Alpha Sales Value by Application (2021-2032)
  12. 5.3.3 Global Interleukin 1 Alpha Sales Value Share by Application (2021-2032)
6 Interleukin 1 Alpha Regional Sales and Value Analysis
  1. 6.1 Global Interleukin 1 Alpha Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Interleukin 1 Alpha Sales by Region (2021-2032)
  3. 6.2.1 Global Interleukin 1 Alpha Sales by Region: 2021-2026
  4. 6.2.2 Global Interleukin 1 Alpha Sales by Region (2027-2032)
  5. 6.3 Global Interleukin 1 Alpha Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Interleukin 1 Alpha Sales Value by Region (2021-2032)
  7. 6.4.1 Global Interleukin 1 Alpha Sales Value by Region: 2021-2026
  8. 6.4.2 Global Interleukin 1 Alpha Sales Value by Region (2027-2032)
  9. 6.5 Global Interleukin 1 Alpha Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Interleukin 1 Alpha Sales Value (2021-2032)
  12. 6.6.2 North America Interleukin 1 Alpha Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Interleukin 1 Alpha Sales Value (2021-2032)
  15. 6.7.2 Europe Interleukin 1 Alpha Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Interleukin 1 Alpha Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Interleukin 1 Alpha Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Interleukin 1 Alpha Sales Value (2021-2032)
  21. 6.9.2 South America Interleukin 1 Alpha Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Interleukin 1 Alpha Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Interleukin 1 Alpha Sales Value Share by Country, 2025 VS 2032
7 Interleukin 1 Alpha Country-level Sales and Value Analysis
  1. 7.1 Global Interleukin 1 Alpha Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Interleukin 1 Alpha Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Interleukin 1 Alpha Sales by Country (2021-2032)
  4. 7.3.1 Global Interleukin 1 Alpha Sales by Country (2021-2026)
  5. 7.3.2 Global Interleukin 1 Alpha Sales by Country (2027-2032)
  6. 7.4 Global Interleukin 1 Alpha Sales Value by Country (2021-2032)
  7. 7.4.1 Global Interleukin 1 Alpha Sales Value by Country (2021-2026)
  8. 7.4.2 Global Interleukin 1 Alpha Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Interleukin 1 Alpha Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Interleukin 1 Alpha Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Interleukin 1 Alpha Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Interleukin 1 Alpha Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Interleukin 1 Alpha Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Interleukin 1 Alpha Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Interleukin 1 Alpha Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Interleukin 1 Alpha Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Interleukin 1 Alpha Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Interleukin 1 Alpha Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Interleukin 1 Alpha Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Interleukin 1 Alpha Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Interleukin 1 Alpha Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Interleukin 1 Alpha Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Interleukin 1 Alpha Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Interleukin 1 Alpha Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Interleukin 1 Alpha Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Interleukin 1 Alpha Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Interleukin 1 Alpha Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Interleukin 1 Alpha Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Interleukin 1 Alpha Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Interleukin 1 Alpha Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Interleukin 1 Alpha Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Interleukin 1 Alpha Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Interleukin 1 Alpha Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Interleukin 1 Alpha Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Interleukin 1 Alpha Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Interleukin 1 Alpha Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Interleukin 1 Alpha Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Interleukin 1 Alpha Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Interleukin 1 Alpha Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Interleukin 1 Alpha Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Interleukin 1 Alpha Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Interleukin 1 Alpha Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Interleukin 1 Alpha Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Interleukin 1 Alpha Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Interleukin 1 Alpha Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Interleukin 1 Alpha Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Interleukin 1 Alpha Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Interleukin 1 Alpha Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Interleukin 1 Alpha Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Interleukin 1 Alpha Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Interleukin 1 Alpha Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Interleukin 1 Alpha Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Interleukin 1 Alpha Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Interleukin 1 Alpha Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Interleukin 1 Alpha Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Interleukin 1 Alpha Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Interleukin 1 Alpha Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Interleukin 1 Alpha Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Interleukin 1 Alpha Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Interleukin 1 Alpha Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Interleukin 1 Alpha Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Interleukin 1 Alpha Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Interleukin 1 Alpha Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Interleukin 1 Alpha Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Interleukin 1 Alpha Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Interleukin 1 Alpha Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Interleukin 1 Alpha Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Interleukin 1 Alpha Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Interleukin 1 Alpha Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Interleukin 1 Alpha Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Interleukin 1 Alpha Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Interleukin 1 Alpha Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Interleukin 1 Alpha Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Interleukin 1 Alpha Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Interleukin 1 Alpha Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Interleukin 1 Alpha Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Interleukin 1 Alpha Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Interleukin 1 Alpha Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Interleukin 1 Alpha Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Interleukin 1 Alpha Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Interleukin 1 Alpha Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Interleukin 1 Alpha Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Interleukin 1 Alpha Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Interleukin 1 Alpha Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Interleukin 1 Alpha Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Interleukin 1 Alpha Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Interleukin 1 Alpha Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Interleukin 1 Alpha Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Interleukin 1 Alpha Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Interleukin 1 Alpha Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Interleukin 1 Alpha Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Interleukin 1 Alpha Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Handok Inc
  2. 8.1.1 Handok Inc Company Information
  3. 8.1.2 Handok Inc Business Overview
  4. 8.1.3 Handok Inc Interleukin 1 Alpha Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Handok Inc Interleukin 1 Alpha Product Portfolio
  6. 8.1.5 Handok Inc Recent Developments
  7. 8.2 XBiotech Inc
  8. 8.2.1 XBiotech Inc Company Information
  9. 8.2.2 XBiotech Inc Business Overview
  10. 8.2.3 XBiotech Inc Interleukin 1 Alpha Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 XBiotech Inc Interleukin 1 Alpha Product Portfolio
  12. 8.2.5 XBiotech Inc Recent Developments
  13. 8.3 AbbVie Inc
  14. 8.3.1 AbbVie Inc Company Information
  15. 8.3.2 AbbVie Inc Business Overview
  16. 8.3.3 AbbVie Inc Interleukin 1 Alpha Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 AbbVie Inc Interleukin 1 Alpha Product Portfolio
  18. 8.3.5 AbbVie Inc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Interleukin 1 Alpha Value Chain Analysis
  2. 9.1.1 Interleukin 1 Alpha Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Interleukin 1 Alpha Sales Mode & Process
  6. 9.2 Interleukin 1 Alpha Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Interleukin 1 Alpha Distributors
  9. 9.2.3 Interleukin 1 Alpha Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst